Symbol
| CISD2
| contributors: mct - updated : 01-09-2018
|
HGNC name
| CDGSH iron sulfur domain 2
|
HGNC id
| 24212
|
corresponding disease(s)
|
WFS2
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
|  
| gain of function
|
in cervical cancer cells at both the mRNA and protein levels | tumoral
|  
|  
|  
| gain of function
|
in lung adenocarcinoma | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| CISD2 expression might be an independent prognostic indicator for the survival of patients with early-stage cervical cancer, and might be a novel biomarker for early-stage cervical cancer progression | Therapy target
|
System | Type | Disorder | Pubmed |
cancer | | | |
promising mitochondrial targets for cancer therapy | diabete | | | |
cellular target for anti-diabetic drugs | neuromuscular | myopathy | | |
novel therapeutic target for treating certain muscle pathologies (PMID: 22343142) | cancer | digestive | liver | |
may serve as a therapeutic target for HCC |
| | |
| Cisd2 deficiency shortens lifespan resulting in premature aging in mice | |
Naf-1 null mice display discernable clinical signs of degeneration at 2-3 months of age, with early evidence of significant defects in the structure and performance of skeletal muscle |